Terry J. Rosen - 23 Jan 2026 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RCUS
Reported as of: 23 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jan 2026, 20:21:47 UTC
Prior SEC filing: 09 Jan 2026
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Carolyn Tang, Attorney-in-Fact

Key filing fact

Terry J. Rosen filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 26 Jan 2026.

Key facts

This page summarizes Terry J. Rosen's Form 4 filing for Arcus Biosciences, Inc. (RCUS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Jan 2026, 20:21.

Change

Previous filing in this sequence was filed on 09 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001182473 Primary reporting owner

ROSEN TERRY J

Relationship: Chief Executive Officer, Director
Address: C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Signature date: 26 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCUS transaction

Common Stock

Award

Transaction value: $0
Shares: +79,000
Change %: +3.7%
Price: $0.000000
Shares after: 2,236,409
Date: 23 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCUS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +315,000
Change %
Price: $0.000000
Shares after: 315,000
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 315,000
Exercise price: $22.13
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

Footnote F2

Includes the unvested portion of the Reporting Person's RSU grants.

Footnote F3

The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.